Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

735
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
735
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

475
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
475
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

497
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
497
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

536
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
536
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

514
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
514
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

674
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
674

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

[Subacute meningoencephalitis following intravesical BCG instillation immunotherapy].

Anales del sistema sanitario de Navarra·2026
Same journal

[Treatment with dabrafenib and trametinib in an intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation].

Anales del sistema sanitario de Navarra·2026
Same journal

[Efficiency after integrating a hospital with a 'new management model'].

Anales del sistema sanitario de Navarra·2026
Same journal

[Anales del Sistema Sanitario de Navarra in 2025: Progress continues].

Anales del sistema sanitario de Navarra·2026
Same journal

Qualitative evaluation of a community intervention in educational centres: Opinion of the professionals involved.

Anales del sistema sanitario de Navarra·2026
Same journal

[Unequal impact of COVID-19 on mortality in long-term care homes across health areas of Castilla-La Mancha (Spain)].

Anales del sistema sanitario de Navarra·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas
04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

775

[Spice intoxication and hyperglycemia].

A Elena-González1, P Cuadros-Tito, G Esteban-Gutiérrez

  • 1Servicio de Medicina Interna. Hospital Universitario Príncipe de Asturias. Alcalá de Henares. Madrid.. aelena83@hotmail.com.

Anales Del Sistema Sanitario De Navarra
|January 31, 2020
PubMed
Summary
This summary is machine-generated.

Synthetic cannabinoid (SC) intoxication can cause hyperglycemia, complicating diagnosis. Suspect SC use in unexplained hyperglycemia, particularly in young patients with agitation or psychosis.

More Related Videos

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.0K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.3K

Related Experiment Videos

Last Updated: Dec 29, 2025

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas
04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

775
Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.0K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.3K

Area of Science:

  • Toxicology
  • Endocrinology
  • Psychiatry

Background:

  • Synthetic cannabinoids (SC) are emerging drugs of abuse with marijuana-like effects but distinct chemical structures.
  • Their unique structure often evades standard drug testing, posing diagnostic challenges.
  • SC use is associated with various adverse health effects, including metabolic disturbances.

Observation:

  • A case of intoxication by synthetic cannabinoids is presented.
  • The patient exhibited symptoms suggestive of SC consumption, alongside unexplained hyperglycemia.
  • Diagnosis was complicated by the difficulty in detecting SC through conventional drug screening.

Findings:

  • Hyperglycemia is identified as a potential side effect of synthetic cannabinoid use.
  • SC intoxication should be considered in cases of unexplained hyperglycemia, especially in younger individuals.
  • Clinical presentations may include agitation, confusion, or psychosis.

Implications:

  • Healthcare providers should consider SC use in differential diagnoses for unexplained hyperglycemia.
  • Increased awareness among diabetic patients regarding SC side effects is crucial due to their vulnerability.
  • Further research is needed to improve SC detection and understand their long-term health impacts.